Provided by Tiger Trade Technology Pte. Ltd.

Nuvation Bio, Inc.

4.95
+0.09001.85%
Post-market: 4.970.0200+0.40%18:36 EDT
Volume:9.29M
Turnover:44.99M
Market Cap:1.74B
PE:-11.28
High:4.98
Open:4.80
Low:4.63
Close:4.86
52wk High:9.75
52wk Low:3.36
Shares:351.12M
Float Shares:264.00M
Volume Ratio:1.15
T/O Rate:3.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4387
EPS(LYR):-0.6000
ROE:-47.81%
ROA:-12.36%
PB:6.85
PE(LYR):-8.25

Loading ...

How Does Nuvation Bio’s (NUVB) IBTROZI Update Reframe Its Long-Term Oncology Investment Narrative?

Simply Wall St.
·
May 20

Nuvation Bio collaborating with Thermo Fisher to manufacture Ibtrozi in NSCLC

TIPRANKS
·
May 14

Nuvation Bio partners with Thermo Fisher for US manufacturing of IBTROZI

Reuters
·
May 14

Nuvation Bio to Collaborate With Thermo Fisher Scientific for U.S.-Based Manufacturing of Ibtrozi® for Ros1-Positive Non-Small Cell Lung Cancer

THOMSON REUTERS
·
May 14

Nuvation Bio says FDA accepts IBTROZI label update filing for ROS1+ NSCLC

Reuters
·
May 06

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for Ibtrozi® (Taletrectinib) With Updated Duration of Response in Advanced Ros1-Positive Non-Small Cell Lung Cancer

THOMSON REUTERS
·
May 06

Nuvation Bio Inc - FDA Accepts Supplemental Nda for Ibtrozi in Advanced Ros1+ Nsclc; Target Action Date Jan 4, 2027

THOMSON REUTERS
·
May 06

Nuvation Bio participates in Bank of America Securities Healthcare Conference fireside chat

Reuters
·
May 06

Stock Track | Nuvation Bio Soars 5.33% Intraday on Positive Analyst Coverage and Maintained Price Targets

Stock Track
·
May 05

Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT), Evolus (EOLS) and Nuvation Bio (NUVB)

TIPRANKS
·
May 05

Nuvation Bio Price Target Maintained With a $17.00/Share by HC Wainwright & Co.

Dow Jones
·
May 05

Earnings Flash (NUVB) Nuvation Bio Posts Q1 EPS $0.01, vs. FactSet Est of $0.03 Loss

MT Newswires Live
·
May 05

Nuvation Bio publishes corporate presentation on IBTROZI ROS1 lung cancer drug```

Reuters
·
May 05

Nuvation Bio Q1 net income turns positive on IBTROZI sales

Reuters
·
May 05

Nuvation Bio Q1 EPS $0.01, Inline, Sales $83.228M Beat $62.259M Estimate.

Benzinga Earnings
·
May 05

BRIEF-Nuvation Bio Q1 EPS USD 0.01

Reuters
·
May 05

Nuvation Bio Q1 Pretax Profit USD 5.397 Million

THOMSON REUTERS
·
May 05

Press Release: Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 05

BRIEF-Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (Ibtrozi®) As Recommended Option

Reuters
·
Apr 27

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (Ibtrozi®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

THOMSON REUTERS
·
Apr 27